Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 Mar 27, 2023 7:00am EDT
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders Mar 07, 2023 7:00am EST
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY Feb 14, 2023 8:00am EST
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement Jan 09, 2023 7:00am EST
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Nov 16, 2022 8:00am EST
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Nov 09, 2022 7:02am EST
